Start Services Company Profile Publications Jobs Customers Contact

vivacell_graurotbuttonklein  Recent news

September 2016

Cooperation with Dhofar University (Sultanate of Oman)


May 2016

We were awarded the Stifterverband's "Innovative through Research" for our research activities.


April 2016

New Version of SimDerma including 30 important dermato-cosmetic parameters.

Read more here.


November 2015:

New Services in neurotoxicity and neuroprotection

Read more here.


October 2015:

SimDerma - new screening platform for cosmetic ingredients.


Read more here.


Services in Oral Care.

Read more here.


September 2015:

Please have a look at our new services in miRNA research.

Read more here.



New publications by VivaCell:


"Poly(I:C) increases the expression of mPGES-1 and COX-2 in rat primary

in J Neuroinflamm. 2016 Jan


"Antimalarial Drug Artemether Inhibits Neuroinflammation in BV2 Microglia
Through Nrf2-Dependent Mechanisms."

in Mol Neurobiol. 2015 Nov


"microRNA-26a modulates inflammatory response induced by toll-like receptor 4 stimulation in microglia."

in J Neurochem, 2015 Sep


"Anti-inflammatory effects of 5-HT3 receptor antagonists in interleukin-1beta stimulated primary human chondrocytes."
in Int Immunopharmacol. 2014 Jun

"Histone deacetylase inhibitors valproic acid and sodium butyrate enhance prostaglandins release in lipopolysaccharide-activated primary microglia."
Neuroscience. 2014 Jan 28



Read more news...



vivacell_graurotbuttonklein  Opinions from our customers:


Dr. G. Weiss (PASCOE pharmazeutische Praeparate GmbH):


"During our well going cooperation over several years, we learned to appreciate VivaCell as a reliable and competent co-operation partner in pre-clinical research. Therefore we are looking forward to continue our successful partnership."  



Read more



Phytodrug / Nutraceuticals
Cardiovascular inflammation
Oncology / Angiogenesis
Oral care
Central Nervous System
Microglia activation studies
Electrophysiological. Meas.
Dermatology / Cosmetics
Permeability Studies
Urinary / Prostata
Animal health
Additional Services
Quality Certificate
SimDerma / Cosmetics
Neurotox testing / Protection
Services in Oral Care


We are awarded for our R&D activities by the Stifterverband:






We are proud members of:









VivaCell Quality-Certificate:




Read more ...





Atherosclerosis is a chronic inflammatory disease of arteries subsequent to hypercholesteronemia and diabetes, that affects both large arteries and microvessels.


The development of early atherosclerotic lesions can be subdivided into initiation (formation of small fatty streaks), expansion (vertical and lateral growth and coalescence of fatty streaks), and progression to plaques (intimal smooth muscle cell recruitment, collagen deposition, and formation of a fibrous cap).


During the initiation and expansion of fatty streaks, circulating monocytes are recruited to the arterial intima, where they are transformed into lipid-engorged macrophage foam cells.The arterial endothelium in these regions is activated and expresses inducible leukocyte adhesion molecules and chemokines.


Although clinically significant complications of atherosclerosis, such as plaque ulceration, rupture, and thrombosis occurs in advanced disease, understanding the mechanism of early lesion formation offers the hope of intervening to delay or prevent lesion progression and complications by using natural compounds from food sources and phytomedicines.


Moreover, in the context of heart pathophysiology, cytokines induced by foam cells in coronary arterial inflammation may have a direct influenced in the cardiac myocytes.


Therefore, VivaCell offers pre-clinical studies for nutraceuticals and phytoextracts using “in vitro” biological test specifically directed to analyse key cellular and molecular targets involved in the progression of the cardiovascular inflammations.





       Sprache         Language          Idioma